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SUMMARY
Circulating antigliadin antibody has been described in patients with gluten
enteropathy although the prevalence varies in different studies. It has been
suggested that the investigation for antigliadin antibody might be useful as a
screening test. The object of the present study was to evaluate two different
techniques for assaying these antibodies - an indirect immunofluorescent
method and an enzyme-linked immunosorbent assay (ELISA). Antibodies were
assayed in the sera of 102patients in whomjejunalbiopsies were also obtained.
The specificity ofboth tests was greater than 95%, and the correlation between
the presence ofantibody and histology was significant (p < 0.005), though the
sensitivity ofeach test was less than 70%.
INTRODUCTION
Detection in patients with gluten-sensitive enteropathy of circulating antibody to
gluten or to one of its components, gliadin, might obviate the need for jejunal
biopsy in diagnosis. However, the prevalence and specificity of tests for antibody
have varied in different studies. In part, this may be due to differences between
adults and children,1 the use of different laboratory techniques,2'3 and the
assessment of different fractions of anti-gliadin antibodies. The IgA fraction has
been shown to be more specific than IgG or IgM4,5'6 and, more recently,
antibody to et gliadin was described as being more sensitive and specific for
coeliac disease than antibody to other wheat proteins tested.7 8 So far, no assay
has yet proved to be an entirely satisfactory screening test for gluten enteropathy.
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The purpose of the present study was to assess the sensitivity and specificity of
the immunofluorescent method used in the Immunology Laboratory, Belfast City
Hospital, and to compare results with those obtained with an enzyme-linked
immunosorbent assay (ELISA) for a gliadin antibody, developed in St James's
Hospital, Dublin.
PATIENTS AND METHODS
From June 1982 to July 1985 all patients undergoing jejunal biopsy at the
Gastroenterology Unit ofthe Belfast City Hospital also had a fasting blood sample
taken for assayofantibody to gliadin. The biopsy was obtained by Crosbycapsule
which was placed endoscopically at a distance of 30cm from the pylorus.9 The
study group comprised 102 patients (61 females, 41 males); their age range was
15 -89 years, their mean age 46.8 years. Fourteen patients were referred with
dermatitis herpetiformis, and four patients who had repeat biopsies during the
period were also included in the series giving atotal of 106jejunal specimens with
corresponding blood samples. Thejejunal biopsies were examined and reported
bythe Histopathology Departmentofthe BelfastCity Hospital. Antibody togliadin
was assayed at the time each blood sample was received in the IgG, IgA and IgM
classes using an immunofluorescent method described by Unsworth et al,3 and
antibody in any immunoglobulin class at a titre of I /10 or greater was considered
positive. The sera were also stored at - 200C and at the end of the study period
those available were sent to St James's Hospital, Dublin, for assay of ae gliadin
antibody using an enzyme-linked immunosorbent assay (ELISA).7 Testing was
carried out without knowledge of thejejunal biopsy appearance, previous results
of antibody testing or diagnosis.
RESULTS
Jejunal biopsy findings
In accordance with accepted criteria,10 jejunal biopsies reported as total atrophy,
sub-total atrophy or as severe partial atrophy were considered significant. With
lesser degrees of atrophy (mild or moderate) they were considered to be of
uncertain significance. In the study group 30 patients had total, sub-total or
severe partial atrophy, 17 had mild or moderate partial atrophy and 59 had
normal histology. Of the 14 patients with dermatitis herpetiformis, five had
significant jejunal atrophy, six mild or moderate partial atrophy and three were
normal.
Incidence ofantibodies to gliadin
Of the 30 patients with significant jejunal histology, 20 (67%) had antibody to
gliadin in IgG, IgA or both immunoglobulin classes detected using the immuno-
fluorescent method. Immunoglobulin G class antibody to gliadin was detected in
19/30 (63%) patients whereas only 10/30 (33%) had IgA antibody, and IgM
class antibody was not detected in any of the samples. Sera for the ELISA assay
of a gliadin antibody were only available in 28 of these 30 cases and antibody
(IgG class) was detected in 18 (64%) (Table 1). There were 16 patients whose
sera were positive with both assays and eight patients in whom both were
negative.
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TABLE I
Titres ofIgG and IgA class antibody togliadin measured by immunofluorescence
and the presence of IgG antibody to a gliadin detected by ELISA in patients
with significantjejunal mucosal atrophy
Antibody to gliadin measured by
Patient Immunofluorescence ELISA
number IgG IgA IgG
1 160 - +
2 160 10 +
3 - 20 +
4 - _ _
5 - _ _
6 - _ _
7 40 -
8 40 10 +
9 80 10 -
10 10 20 +
11 10 - +
12 10 - +
13 40 10 +
14 160 40 NA*
15 20 - +
16 40 - +
17 - - +
18 20 - +
19 - - -
20 80 - +
21 10 - +
22 - - +
23 - - -
24 - - _
25 40 10 +
26 20 10 +
27 - - -
28 80 80 NA*
29 - - -
30 20 - +
Number
positive 19 (63%) 10 (33%) 18 (64%)
*NA = Not available.
For the cases with mild or moderate partial atrophy two out of 17 had detectable
gliadin antibodies using the immunofluorescent method, and the ELISA test for
a gliadin antibody was positive in two different cases (Table 11). The incidence of
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positivity in this group ofpatients, using both methods, was less than in the group
with significant histology (p< 0.005 using Chi square analysis).
TABLE II
Incidence of antibody to gliadin measured by immunofluorescence and ELISA
in relation tojejunal histology
Number ofpatients with antibody
to gliadin measured by
Histology Immunofluorescence ELISA
Total, sub-total or severe partial atrophy 20/30 (67%) 18/28 (64%)
Mild or moderate partial atrophy 2/17 (12%) 2/17 (12%)
Normal 1/59 ( 2%) 3/59 ( 5%)
For the 59 subjects with normal histology, one was positive using both the
immunofluorescent and ELISA methods. A further two cases were positive with
the ELISA test alone. The percentages positive with both methods were less than
for the group with significant histology (p< 0.005).
The sensitivity of each test was expressed as the percentage of cases positive in
the significant histology group, hence the immunofluorescent method was 67%
and the ELISA method 64% sensitive. The specificity was expressed as the
percentage of cases which were negative in the normal histology group. For the
immunofluorescent method this was 98.3% compared with 95% for the ELISA
test.
DISCUSSION
This study has demonstrated that there is excellent correlation between the
presence ofcirculating gliadin antibodies and severity ofjejunal mucosal atrophy.
The ELISA testforantibody to gliadin wassimilarin detection rate to the currently
used immunofluorescent test for gliadin antibodies. It could be argued that
storage of sera may in some way have impaired the sensitivity of the ELISA test,
but, as a check, the immunofluorescent tests were repeated at the end of the
study period on the same stored sera and these showed no difference from the
original results.
Although the specificity of both tests was high, their sensitivities were unaccept-
ably low (67%, 64% respectively) with one-third of patients with gluten
enteropathy being undetected. Previous studies indicate that detection of gliadin
antibodies is more likely amongst children than amongst adult patients with
coeliac disease.1 6 In our study the age range of patients with significant jejunal
mucosal atrophy was 17 to 81 years, mean age 45 years, and therefore our
conclusions can only be applied to an adult population.
In a previous study of a group of patients with coeliac disease, in the Republic
of Ireland, the detection of a gliadin antibody by the ELISA technique had a
sensitivity of 82% and a specificity of 85%.7 This higher incidence of both
true positives and false positives may reflect genetic differences between the
populations in different parts of Ireland.
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In the group with mild or moderate villous atrophy, it is probable that some of
these cases did not have gluten sensitivity. However, four of the biopsies in this
group were repeat tests taken after a gluten-free diet and showed significant
histological improvement compared with their initial biopsies. Also a further
patient from this group showed significant improvement in a subsequent biopsy
after a gluten-free diet. These five patients were therefore definitely gluten-
sensitive, but only one had detectable antibody (by immunofluorescence).
Although the number of patients was small, this observation tends to emphasise
the association of detectable antibody with severe histological changes and not
with gluten sensitivity per se. This is in keeping with a number of prospective
studies which have demonstrated that antibodies to gliadin tend to disappear in
patients who take a gluten-free diet and who show histological improvement.2,5,7
The specificity of both tests was very favourable butthere were a small number of
false positives in the group with normal histology. One patient who had Crohn's
disease had antibody with both assays. Such false positives have been described
in Crohn's disease and in various other conditions including ulcerative colitis and
postenteritis syndrome.6
The presence of antibodies to gliadin in IgA class have been described as being a
better indicator ofgluten enteropathy than those in IgG class4.5,6 but this was not
evident from the present study, when their incidence was lower. In our hands,
measurement of IgA antigliadin antibodies alone would be less useful than both
IgG and IgA. As guidance to the clinician we have shown that a positive test for
gliadin antibody with the currently used immunofluorescent method is highly
specific. There is a strong chance that a positive result indicates gluten entero-
pathy. However, a negative result does not exclude it, and the present sensitivity
makes it unsuitable for use as a single screening test.
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